ABCB1 and escherichia coli infection: To investigate whether E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting the intestinal P-glycoprotein expression, the pharmacokinetics of enrofloxacin was also studied after exposure to verapamil (a potent and selective inhibitor of P-gp inhibitor) for 30 min in both healthy and infected groups.